6-Hydroxy-1-isopropyl-4-(4-isopropylphenyl)-1H-quinazolin-2-one, 97%, 100mg

Pyrrolidine-2,5-diyldimethanol, 95.0%, 100mg

2-Amino-5-bromo-3,4-dimethylbenzoic acid, 98%, 1g

Ethyl 2-Methylnicotinate, 97.0%, 100g

BICYCLO[2.2.1]HEPTANE, 2-(2,2-DIFLUOROETHENYL)-, 95%, 250mg

1-Chloro-3,5-difluoro-2-isothiocyanatobenzene, 97.0%, 1g

Phase contrast slide with phase rings for PLPH 20x and S100x oil plan phase objectives

2-Hydroxymethyl-3-methyl-4-nitropyridine, 95+%, 250mg

7-Bromo-4,4-dimethyl-1,2,3,4-tetrahydroisoquinoline hydrochloride, 95.0%, 1g

5-Chloroisoindoline, 95.0%, 1g

2,6-Dimethylheptan-4-ol, 85.0%, 25g

(R)-METHYL 2-((TERT-BUTOXYCARBONYL)AMINO)-3-((TERT-BUTYLDIMETHYLSILYL)OXY)PROPANOATE, 95.0%, 1g

tert-Butyl 4-(5-aminopyrimidin-2-yl)piperazine-1-carboxylate, 1g